DAWES KAREN A
SEC insider (Form 3/4/5 filer). CIK 0001261506. Director at Barinthus Biotherapeutics plc. (BRNS) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Sep 9, 2026. Located in GERMANTOWN, MD.
Companies DAWES KAREN A has filed insider reports for
- Barinthus Biotherapeutics plc. (BRNS): Director
- REPLIGEN CORP (RGEN): Director
DAWES KAREN A
CIK: 0001261506
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (60.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (20.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Sep 9, 2026BRNS
Barinthus Biotherapeutics plc.
DispositionDirect1.7K shares- - May 14, 2026RGEN
REPLIGEN CORP
AwardDirect995 shares- - Dec 17, 2025RGEN
REPLIGEN CORP
SaleDirect275 shares at avg. $161.00$44K - Jun 10, 2025BRNS
Barinthus Biotherapeutics plc.
AwardDirectShare Option (Right to Buy)
20.2K shares- - May 15, 2025RGEN
REPLIGEN CORP
AwardDirect973 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 9, 2026 |  BRNS Barinthus Biotherapeutics plc. | Disposition | 1,700 | - | $0 | Direct |
| May 14, 2026 |  RGEN REPLIGEN CORP | Award | 995 | - | $0 | Direct |
| Dec 17, 2025 | RGEN REPLIGEN CORP | Sale | 275 | $161.00 | $44,275 | Direct |
| Jun 10, 2025 | BRNS Barinthus Biotherapeutics plc. | Award Share Option (Right to Buy) | 20,174 | - | - | Direct |
| May 15, 2025 | RGEN REPLIGEN CORP | Award | 973 | - | - | Direct |
1-5 of 5 transactions